...
首页> 外文期刊>Renal failure. >Shenfushu granule and atropine attenuate microvasculature loss in rat models with 5/6 nephrectomy
【24h】

Shenfushu granule and atropine attenuate microvasculature loss in rat models with 5/6 nephrectomy

机译:肾复舒颗粒和阿托品减轻5/6肾切除大鼠模型的微脉管系统丧失

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: To investigate the effect of Shenfushu granule (SFSG) and atropine treatment on microvessels of the kidney and intestine after chronic renal failure (CRF) induced by 5/6 nephrectomy. Methods: Sprague Dawley rats were randomly divided into a sham group, a model group, an SFSG group, and an SFSG atropine group. SFSG was administered daily 1 week after inducing CRF. Rats were sacrificed at the end of the eighth week. Urinary protein and stool and serum urea nitrogen (UN) and creatinine (Cr) levels were assessed. Hematoxylin and eosin and periodic acid-Schiff staining of the kidney and examination of the vascular endothelial growth factor (VEGF) and microvessel density (MVD) levels in kidney and intestine were performed. Results: The Cr and UN levels were significantly increased in blood and stool of the model group. SFSG significantly improved renal function, and the protective effects were further enhanced with the addition of atropine. Glomerular sclerosis, tubulointerstitial fibrosis, and microvessel loss were observed in CRF rats, and these pathological changes were ameliorated in the two treatment groups (p < 0.05), especially in the SFSG atropine group. The expression of VEGF and MVD was decreased in the CRF rats compared with the sham group. SFSG treatment increased the expression of these proteins and reversed the degree of microvessel loss, glomerular sclerosis, and tubulointerstitial fibrosis (p < 0.05). Co-treatment with atropine enhanced these effects. Conclusions: SFSG alleviated renal function, upregulated the expression of VEGF and MVD in the kidney and intestine, and attenuated the degree of microvessel loss, glomerular sclerosis, and tubulointerstitial fibrosis in the early stages of CRF in rats, and addition of atropine enhanced these effects.
机译:目的:探讨参附舒颗粒(SFSG)和阿托品治疗对5/6型肾切除术后慢性肾衰竭(CRF)后肾和肠微血管的影响。方法:将SD大鼠随机分为假手术组,模型组,SFSG组和SFSG阿托品组。诱导CRF后1周每天给予SFSG。在第八周结束时处死大鼠。评估尿蛋白和粪便以及血清尿素氮(UN)和肌酐(Cr)的水平。进行苏木精和曙红和肾脏的高碘酸-希夫(Schiff)染色以及检查肾脏和肠中的血管内皮生长因子(VEGF)和微血管密度(MVD)水平。结果:模型组血液和粪便中的Cr和UN水平显着升高。 SFSG显着改善了肾功能,并且添加了阿托品进一步增强了保护作用。在CRF大鼠中观察到肾小球硬化,肾小管间质纤维化和微血管丢失,并且在两个治疗组中这些病理改变得到改善(p <0.05),特别是在SFSG阿托品组中。与假手术组相比,CRF大鼠的VEGF和MVD表达降低。 SFSG治疗增加了这些蛋白质的表达,并逆转了微血管丢失,肾小球硬化和肾小管间质纤维化的程度(p <0.05)。与阿托品共同治疗可增强这些作用。结论:SFSG可减轻大鼠CRF早期的肾功能,上调肾脏和肠中VEGF和MVD的表达,并减轻微血管丢失,肾小球硬化和肾小管间质纤维化的程度,并加入阿托品可增强这些作用。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号